Atossa Therapeutics, Inc.
ATOS
$0.6231
$0.01812.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.38% | -0.93% | -13.11% | -9.97% | 6.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.71% | -14.50% | -8.83% | -1.66% | 10.83% |
| Operating Income | 20.71% | 14.50% | 8.83% | 1.66% | -10.83% |
| Income Before Tax | 18.15% | -16.07% | 38.46% | 6.42% | -3.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.15% | -16.07% | 38.46% | 6.42% | -3.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.15% | -16.07% | 38.46% | 6.42% | -3.51% |
| EBIT | 20.71% | 14.50% | 8.83% | 1.66% | -10.83% |
| EBITDA | 20.63% | 14.52% | 8.84% | 1.69% | -10.68% |
| EPS Basic | 19.06% | -16.16% | 38.02% | 5.44% | -4.56% |
| Normalized Basic EPS | 19.12% | 11.33% | 10.95% | 5.48% | -4.59% |
| EPS Diluted | 19.06% | -16.16% | 38.02% | 5.44% | -4.56% |
| Normalized Diluted EPS | 19.12% | 11.33% | 10.95% | 5.48% | -4.59% |
| Average Basic Shares Outstanding | 1.05% | -0.02% | -0.70% | -1.03% | -1.05% |
| Average Diluted Shares Outstanding | 1.05% | -0.02% | -0.70% | -1.03% | -1.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |